Bamco Inc. NY Invests $13.03 Million in CareDx, Inc (NASDAQ:CDNA)

Bamco Inc. NY acquired a new stake in shares of CareDx, Inc (NASDAQ:CDNA) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,229,900 shares of the company’s stock, valued at approximately $13,025,000. Bamco Inc. NY owned approximately 2.36% of CareDx as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of CareDx by 87.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 228,198 shares of the company’s stock valued at $2,417,000 after acquiring an additional 106,660 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in CareDx by 138.9% in the fourth quarter. Los Angeles Capital Management LLC now owns 237,115 shares of the company’s stock valued at $2,845,000 after purchasing an additional 137,842 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of CareDx by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 4,138,591 shares of the company’s stock worth $28,970,000 after purchasing an additional 50,667 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of CareDx by 10,267.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 18,661 shares of the company’s stock worth $198,000 after purchasing an additional 18,481 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in shares of CareDx in the 4th quarter valued at approximately $117,000.

CareDx Stock Performance

Shares of CareDx stock traded up $0.14 during trading on Friday, reaching $19.01. The company’s stock had a trading volume of 1,198,160 shares, compared to its average volume of 571,294. CareDx, Inc has a one year low of $4.80 and a one year high of $19.58. The firm has a market cap of $990.12 million, a price-to-earnings ratio of -5.56 and a beta of 1.78. The business’s fifty day moving average price is $15.49 and its 200-day moving average price is $11.87.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.18. CareDx had a negative return on equity of 55.08% and a negative net margin of 66.59%. The company had revenue of $72.05 million for the quarter, compared to the consensus estimate of $63.63 million. Sell-side analysts anticipate that CareDx, Inc will post -1.49 EPS for the current year.

Analyst Ratings Changes

CDNA has been the subject of a number of analyst reports. Craig Hallum lifted their target price on shares of CareDx from $15.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, May 17th. HC Wainwright reissued a “neutral” rating on shares of CareDx in a research report on Friday, May 31st. Stephens upped their price target on CareDx from $15.00 to $18.00 and gave the stock an “overweight” rating in a research note on Monday, May 13th. Raymond James lowered CareDx from an “outperform” rating to a “market perform” rating in a report on Monday, May 13th. Finally, The Goldman Sachs Group increased their price target on CareDx from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, July 17th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.00.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.